US Myocardial Infarction Market, Size, Share, Analysis Report & Forecast to 2026

Posted September 15, 2021 by alfahadkhan2510

The US myocardial infarction (MI) market is estimated to grow modestly at a CAGR of around 6.4% during the forecast period.

The US myocardial infarction (MI) market is estimated to grow modestly at a CAGR of around 6.4% during the forecast period. The US contributes significantly to the growth of the MI treatment market in North America. The increasing prevalence of heart diseases, high per capita healthcare expenditure and well-developed healthcare infrastructure are the key factors to promote the growth of the myocardial infarction treatment market in the US. The US is expected to make a major contribution to the MI treatment market due to the rise in the adoption of hybrid operating rooms and innovative treatment technology. Hospitals and clinics in the US are well equipped with the latest treatment devices which are essential to perform critical MI surgeries. Cleveland Clinic, Mayo Clinic, New York-Presbyterian University Hospital of Columbia and Cornell are some of the key hospitals contributing to the growth of the MI treatment market. In 2019, the average cardiology procedures which include bypass surgery ranges from $56,000 to $200,000 in the US. The cost of heart valve replacement surgery costs around $80,000- $200,000. Additionally, various physical therapies followed by surgery may cost around $50-$350 per session, according to the Center for Medicare & Medicaid Services.

Free Sample Copy @

The market study of the US myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

A Full Report of US Myocardial Infarction Market is Available at:

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST segment elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The companies which are contributing to the growth of the US myocardial infarction market include Johnson & Johnson Services Inc., Mylan N.V., Pfizer Inc., Bayer AG, and Novartis AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

US Myocardial Infarction Market – Segmentation
by Type
Non-ST-elevation myocardial infarction (NSTEMI)
ST-elevation myocardial infarction (STEMI)
Silent Heart Attacks
by Device
Left Ventricular Assist Device (LVAD)
Implantable Cardioverter-Defibrillator (ICD)
Others (Stent Graft)
by Diagnosis
Electrocardiography (ECG)
Chest X-Ray
Computed Tomography (CT Scan)
Others (Blood Test)
by Treatment
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Others (Beta-Adrenergic Blockers)
Bypass Surgery
Heart Transplant
by End-User
Hospital & Clinics
Ambulatory Surgical Centers
Research Institutes

Company Profiles
Abbott Laboratories Inc.
AstraZeneca PLC
Athersys Inc.
Bayer AG
Biovascular Inc.
Boston Scientific Corp.
Bristol-Myers Squibb Co.
Caladrius Bioscience Inc.
Capricor Therapeutics, Inc.
Eli Lilly and Co.
GlaxoSmithKline Plc
Johnson & Johnson Services, Inc.
Medtronic PLC
Merck KGaA
Mylan N.V.
Novartis AG
Osiris Therapeutics Inc.
Pfizer Inc.
Portola Pharmaceutical Inc.
Siemens AG
Ventrix, Inc.

For More Customized Data, Request for Report Customization @

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Alfahad khan
Phone +91 780-304-0404
Country India
Categories Business
Tags us myocardial infarction market
Last Updated September 15, 2021